Contrasting Trius Therapeutics (TSRX) & Onconova Therapeutics (ONTX)

Trius Therapeutics (NASDAQ: TSRX) and Onconova Therapeutics (NASDAQ:ONTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Institutional & Insider Ownership

12.7% of Onconova Therapeutics shares are held by institutional investors. 13.3% of Onconova Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Trius Therapeutics and Onconova Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trius Therapeutics N/A N/A N/A ($1.60) N/A
Onconova Therapeutics $790,000.00 23.99 -$24.09 million ($2.82) -0.35

Trius Therapeutics has higher earnings, but lower revenue than Onconova Therapeutics. Onconova Therapeutics is trading at a lower price-to-earnings ratio than Trius Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Trius Therapeutics and Onconova Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trius Therapeutics 0 0 0 0 N/A
Onconova Therapeutics 0 1 3 0 2.75

Onconova Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 700.00%.


This table compares Trius Therapeutics and Onconova Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trius Therapeutics N/A N/A N/A
Onconova Therapeutics -3,061.37% -558.97% -207.61%

Trius Therapeutics Company Profile

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Receive News & Ratings for Trius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trius Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply